Austar Lifesciences Ltd
HKEX:6118
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Austar Lifesciences Ltd
Operating Income
Austar Lifesciences Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Austar Lifesciences Ltd
HKEX:6118
|
Operating Income
¥48.2m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
13%
|
CAGR 10-Years
31%
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Operating Income
¥16.3B
|
CAGR 3-Years
20%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Operating Income
¥2.1B
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Operating Income
¥7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Operating Income
¥687.5m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
13%
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Operating Income
¥1.8B
|
CAGR 3-Years
129%
|
CAGR 5-Years
119%
|
CAGR 10-Years
N/A
|
|
Austar Lifesciences Ltd
Glance View
Austar Lifesciences Ltd. operates as an investment holding company. The company is headquartered in Beijing, Beijing. The company went IPO on 2014-11-07. The firm operates its business through six segments: liquid and bioprocess system segment, clean room and automation control and monitoring system segment, powder and solid system segment, good manufacturing practice (GMP) compliance service segment, life science consumables segment and distribution and agency of pharmaceutical equipment segment.
See Also
What is Austar Lifesciences Ltd's Operating Income?
Operating Income
48.2m
CNY
Based on the financial report for Dec 31, 2025, Austar Lifesciences Ltd's Operating Income amounts to 48.2m CNY.
What is Austar Lifesciences Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
31%
Over the last year, the Operating Income growth was 26%. The average annual Operating Income growth rates for Austar Lifesciences Ltd have been -27% over the past three years , 13% over the past five years , and 31% over the past ten years .
